Be Clinical Secures Rs 6 Crore in Seed Funding Led by V3 Ventures

Be Clinical, an evidence-led skincare brand focused on clinically effective solutions for ageing skin, has raised Rs 6 crore in seed funding. The funding round was led by V3 Ventures, with participation from Titan Capital founded by Kunal Bahl and Rohit Bansal, who have strengthened their commitment to the brand.

Founded by Hemangi Dhir, Be Clinical was launched to address a clear gap in the Indian skincare market — the lack of science-led, transparent, and clinically validated solutions designed specifically for Indian skin and environmental conditions. At a time when many brands are driven by marketing claims or rely on expensive, clinic-based treatments, Be Clinical positions itself around in-vivo tested, clinically validated formulations, supported by end-to-end in-house research.

The seed funding will be used to cater three major areas. Firstly, it will support research and development, aimed at enhancing in-house formulation capabilities, conducting clinical trials, and building targeted solutions for ageing concerns across the face, body and scalp. Moving ahead, the company will also scale its manufacturing operations by investing in advanced machinery to improve capacity and quality standards. Additionally, some part of the capital will be used to upgrade packaging to provide ingredient efficacy.

Since its launch in May 2025, Be Clinical has served over 25,000 customers as of December 31, 2025, signalling strong early traction. The growth highlights increasing consumer demand for science-backed skincare tailored for Indian conditions.

Speaking on the launch, Arjun Vaidya, Co-Founder at V3 Ventures said, “At V3, we are seeing a big change in the beauty and personal care space. Customers have moved from being generalists to knowledgeable specific. We believe anti-aging is a massive, untapped space that starts seeing relevance in a consumer's mind in their mid 20s.”

This launch proves a clear market demand for science-backed formulations that prioritise efficacy, transparency, and education over trend-based claims.